http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 17:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Cadrenal+Therapeutics%2C++++For%3A+Jul+23/26809142.html si-local-file:///var/storage/secattach/20260723/26809142.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Cadrenal+Therapeutics%2C++++For%3A+Jul+23/26809142.html Thu, 23 Jul 2026 17:22:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Cadrenal+Therapeutics%2C++++For%3A+Jul+23/26809142.html si-local-file:///var/storage/secattach/20260723/26809142.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Cadrenal+Therapeutics%2C++++For%3A+Jul+23/26809142.html Thu, 23 Jul 2026 17:22:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+21/26792841.html si-local-file:///var/storage/secattach/20260721/26792841.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+21/26792841.html Tue, 21 Jul 2026 08:31:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+21/26792841.html si-local-file:///var/storage/secattach/20260721/26792841.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+21/26792841.html Tue, 21 Jul 2026 08:31:00 -0400 CVKD O.54961393 http://www.streetinsider.com/Corporate+News/Cadrenal+Therapeutics+seeks+partners+for+cardiac+drug+portfolio/26792614.html <p>Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced it has initiated a structured process to secure out-licensing, portfolio monetization, or co-development partnerships for its late-stage cardiovascular drug assets, according to a press release dated July 21, 2026.</p><p>The Ponte Vedra, Fla.-based biopharmaceutical company said it has organized its clinical pipeline into what it calls a Cardiac Acute Critical Care Franchise, comprising three assets: CAD-1005, frunexian, and tecarfarin.</p><p>CAD-1005 is an investigational intravenous 12-lipoxygenase (12-LOX) inhibitor being developed for heparin-induced thrombocytopenia (HIT), a condition that can occur following cardiac surgery. The company said Phase 2 data presented at the International Society on Thrombosis and Haemostasis http://www.streetinsider.com/Corporate+News/Cadrenal+Therapeutics+seeks+partners+for+cardiac+drug+portfolio/26792614.html Tue, 21 Jul 2026 08:03:32 -0400 CVKD http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html <ul type="disc"><li><em>Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions</em></li><li><em>Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin</em></li><li><em>Recently presented Phase 2 CAD-1005 data demonstrated a &gt;25% absolute reduction in thrombotic events in patients with </em>heparin-induced thrombocytopenia<br/></li></ul> <p>PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WHDsMWHBnAWpzIReaedXqHq5_3XP04o9tyeENFiIbaGFKdA4kZjW97_zDNCurzbxctMTQNyH8qE58mURr0FF62_j8rDlFlpMD98FnlOgHrNTBBTRf91VVnS7UDgabWAPR8aEZH9C3-CO2XJPPEetjg==" rel="nofollow" target="_blank">Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)</a>, a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise. Concurrently, http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+Launches+Partnering+Process+as+Its+Cardiac+Acute+Critical+Care+Assets+Advance+to+Transaction+Readiness+Following+Landmark+ISTH+Data+Presentation/26792538.html Tue, 21 Jul 2026 08:00:00 -0400 A.06822034 A.31066700 CVKD O.20026344 O.22422661 O.54961393 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Cadrenal+Therapeutics%2C+++++++++++++++/26791623.html si-local-file:///var/storage/secattach/20260721/26791623.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Cadrenal+Therapeutics%2C+++++++++++++++/26791623.html Tue, 21 Jul 2026 06:04:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Cadrenal+Therapeutics%2C+++++++++++++++/26791623.html si-local-file:///var/storage/secattach/20260721/26791623.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Cadrenal+Therapeutics%2C+++++++++++++++/26791623.html Tue, 21 Jul 2026 06:04:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Cadrenal+Therapeutics%2C+++++++++++++++/26790148.html si-local-file:///var/storage/secattach/20260720/26790148.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Cadrenal+Therapeutics%2C+++++++++++++++/26790148.html Mon, 20 Jul 2026 16:38:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Cadrenal+Therapeutics%2C+++++++++++++++/26790148.html si-local-file:///var/storage/secattach/20260720/26790148.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Cadrenal+Therapeutics%2C+++++++++++++++/26790148.html Mon, 20 Jul 2026 16:38:00 -0400 CVKD O.54961393 http://www.streetinsider.com/Corporate+News/Cadrenal+Therapeutics+CMO+resigns%2C+separation+terms+disclosed/26784601.html <p>Cadrenal Therapeutics (NASDAQ: CVKD) has entered into a separation agreement with James J. Ferguson III, its Chief Medical Officer, following his resignation announced July 7, 2026.</p><p>According to a company statement, Dr. Ferguson notified the board of his decision to resign effective July 31, 2026. The separation agreement, dated July 9, 2026, was formally entered into on July 14, 2026.</p><p>Under the terms of the agreement, Dr. Ferguson will receive his current salary through his last day, reimbursement of approved business expenses, and up to six months of COBRA health insurance premium payments, provided he remains eligible and does not obtain coverage http://www.streetinsider.com/Corporate+News/Cadrenal+Therapeutics+CMO+resigns%2C+separation+terms+disclosed/26784601.html Fri, 17 Jul 2026 16:21:02 -0400 CVKD http://www.streetinsider.com/Management+Changes/Cadrenal+Therapeutics+CMO+resigns%2C+separation+terms+disclosed/26784601.html <p>Cadrenal Therapeutics (NASDAQ: CVKD) has entered into a separation agreement with James J. Ferguson III, its Chief Medical Officer, following his resignation announced July 7, 2026.</p><p>According to a company statement, Dr. Ferguson notified the board of his decision to resign effective July 31, 2026. The separation agreement, dated July 9, 2026, was formally entered into on July 14, 2026.</p><p>Under the terms of the agreement, Dr. Ferguson will receive his current salary through his last day, reimbursement of approved business expenses, and up to six months of COBRA health insurance premium payments, provided he remains eligible and does not obtain coverage http://www.streetinsider.com/Management+Changes/Cadrenal+Therapeutics+CMO+resigns%2C+separation+terms+disclosed/26784601.html Fri, 17 Jul 2026 16:21:02 -0400 CVKD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+14/26784503.html si-local-file:///var/storage/secattach/20260717/26784503.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+14/26784503.html Fri, 17 Jul 2026 16:15:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+14/26784503.html si-local-file:///var/storage/secattach/20260717/26784503.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+Jul+14/26784503.html Fri, 17 Jul 2026 16:15:00 -0400 CVKD O.54961393